Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cesare Celeste Berra"'
Autor:
Valeria Pellegrini, Rosalba La Grotta, Francesca Carreras, Angelica Giuliani, Jacopo Sabbatinelli, Fabiola Olivieri, Cesare Celeste Berra, Antonio Ceriello, Francesco Prattichizzo
Publikováno v:
Cells, Vol 13, Iss 19, p 1662 (2024)
Low-grade inflammation (LGI) represents a key driver of type 2 diabetes (T2D) and its associated cardiovascular diseases (CVDs). Indeed, inflammatory markers such as hs-CRP and IL-6 predict the development of T2D and its complications, suggesting tha
Externí odkaz:
https://doaj.org/article/5be04407d8f54fb0a87a1c6fcc8823be
Autor:
Cesare Celeste Berra, Lorenzo Pradelli
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 22, Iss 2S (2021)
Over the past 20 years, the prevalence of diabetes in Italy has been growing, up to the current estimated proportion of about 8.5%, which accounts also for undiagnosed patients. As most of these subjects are >65 years of age, the probability of havin
Externí odkaz:
https://doaj.org/article/db3d7ceefb5e4f7b98e64343cb5c0af6
Autor:
Cesare Celeste Berra, Roberto Manfrini, Marco Mirani, Loredana Bucciarelli, Amhed S Zakaria, Sara Piccini, Renata Ghelardi, Maria Elena Lunati, Sylka Rodovalho, Francesco Bifari, Paolo Fiorina, Franco Folli
Background Cardiovascular (CV) risk assessment may result unpractical in real-world clinical practice, although being considered a key step for choosing appropriate therapies for patients with Type 2 Diabetes Mellitus (T2DM). In order to streamline t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6ff8028e93a496341728e56799aa60c
https://doi.org/10.21203/rs.3.rs-2134695/v2
https://doi.org/10.21203/rs.3.rs-2134695/v2
Autor:
Rosalba La Grotta, Paola de Candia, Fabiola Olivieri, Giulia Matacchione, Angelica Giuliani, Maria Rita Rippo, Elena Tagliabue, Monica Mancino, Francesca Rispoli, Sabina Ferroni, Cesare Celeste Berra, Antonio Ceriello, Francesco Prattichizzo
Sodium–glucose cotransporter 2 (SGLT-2) inhibitors (i) reduce cardiovascular and renal events in patients with and without type 2 diabetes (T2D). However, the underlying mechanisms are debated. Low-grade inflammation (LGI) is a key driver of vascul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4105eab21d35217d00726a955e9c991a
https://hdl.handle.net/11588/913861
https://hdl.handle.net/11588/913861